<DOC>
	<DOCNO>NCT02924402</DOCNO>
	<brief_summary>This study determine dose schedule XmAb13676 treatment CD20 express hematologic malignancy .</brief_summary>
	<brief_title>Study Evaluate Safety Tolerability XmAb13676 Patients With CD20-expressing Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<criteria>Able provide write informed consent Diagnosis either NonCLL B cell malignancy CLL/SLL Ineligible exhaust standard therapeutic option Last dose antiCD20 antibody therapy must &gt; 4 week study entry ECOG performance status 02 Not candidate refuse treatment hematopoietic stem cell transplantation Fertile patient must agree use effective contraception 4 week completion study Able willing complete entire study Cytotoxic chemotherapy , radiotherapy , immunotherapy within 4 week , small molecule investigational agent within 6 elimination halflives Prior allogeneic stem cell solid organ transplantation Failure recover Grade 3 4 toxicity previous treatment Multiple myeloma/plasma cell leukemia B cell acute lymphoblastic leukemia Known intolerance CD20 monoclonal antibody therapy History primary central nervous system lymphoma neoplastic central nervous system disease Platelet count &lt; 50 x 10^9/L Absolute neutrophil count &lt; 1.0 x 10^9/L Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) screen &gt; 3x upper limit normal ( ULN ) Bilirubin &gt; 1.5 mg/dL Estimated creatinine clearance &lt; 50 mL/min Active/uncontrolled autoimmune disease Clinically significant cardiac/cardiovascular disease , pulmonary compromise Seizure disorder History stroke past year History evidence clinically unstable/uncontrollable disorder , condition disease primary malignancy , opinion Investigator would pose risk patient safety interfere study evaluation , procedure completion Evidence serious bacterial , viral , parasitic systemic fungal infection within 30 day prior study entry Positive test human immunodeficiency virus ( HIV ) hepatitis C antibody Positive test HbsAg , positive test HBcAb ( unless serology positive due recent intravenous immunoglobulin therapy ) Patient pregnant breast feeding , plan become pregnant enrolled study , End Study visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>NHL</keyword>
	<keyword>B-cell Prolymphocytic Leukemia</keyword>
	<keyword>Transformed Lymphoma</keyword>
	<keyword>Burkitt 's Lymphoma</keyword>
	<keyword>Mantle Cell Lymphoma</keyword>
	<keyword>Hairy Cell Leukemia</keyword>
	<keyword>Splenic Marginal Zone Lymphoma</keyword>
	<keyword>Waldenstrom 's Macroglobulinemia</keyword>
	<keyword>Variant Hairy Cell Leukemia</keyword>
	<keyword>Splenic B-cell Lymphoma/Leukemia</keyword>
	<keyword>Lymphoplasmacytic Lymphoma</keyword>
	<keyword>Extranodal Marginal Zone Lymphoma Mucosa-Associated Lymphoid Tissue ( MALT )</keyword>
	<keyword>MALT Lymphoma</keyword>
	<keyword>Nodal Marginal Zone Lymphoma</keyword>
	<keyword>Follicular Lymphoma</keyword>
	<keyword>In Situ Follicular Neoplasia</keyword>
	<keyword>Duodenal-type Follicular Lymphoma</keyword>
	<keyword>Large B-cell Lymphoma IRF4 rearrangement</keyword>
	<keyword>Primary Cutaneous Follicle Center Lymphoma</keyword>
	<keyword>Diffuse Large B-cell Lymphoma</keyword>
	<keyword>DLBCL</keyword>
	<keyword>T-cell/Histiocyte-Rich Large B-cell Lymphoma</keyword>
	<keyword>Primary Cutaneous DLBCL , leg type</keyword>
	<keyword>EBV-positive DLBCL , NOS</keyword>
	<keyword>EBV-positive Mucocutaneous Ulcer</keyword>
	<keyword>DLBCL Associated Chronic Inflammation</keyword>
	<keyword>Lymphomatoid Granulomatosis</keyword>
	<keyword>Primary Mediastinal ( Thymic ) Large B-cell Lymphoma</keyword>
	<keyword>Intravascular Large B-cell Lymphoma</keyword>
	<keyword>ALK+ Large B-cell Lymphoma</keyword>
	<keyword>Plasmablastic Lymphoma</keyword>
	<keyword>Primary Effusion Lymphoma</keyword>
	<keyword>HHV8+ DLBCL</keyword>
	<keyword>Burkitt-like Lymphoma 11q Aberration</keyword>
	<keyword>High-grade B-cell Lymphoma</keyword>
	<keyword>B-cell Lymphoma , unclassifiable</keyword>
	<keyword>Post-transplant Lymphoproliferative Disorder</keyword>
	<keyword>PTLD</keyword>
	<keyword>CLL</keyword>
	<keyword>SLL</keyword>
	<keyword>High-grade Lymphoma</keyword>
</DOC>